Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,110 across all filing types
Latest filing 2023-08-07 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Successful Completion of 2nd DSMB Review of FSGS Trial 3 pages 388.7KB
Regulatory Filings
2023-08-07 English
Investor Presentation 26 pages 4.4MB
Regulatory Filings
2023-07-31 English
Quarterly Appendix 4C and Activities Report 9 pages 662.6KB
Regulatory Filings
2023-07-27 English
DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24 4 pages 416.9KB
Regulatory Filings
2023-07-23 English
Dimerix presentation at Bioshares Biotech Summit 19 pages 2.8MB
Regulatory Filings
2023-07-23 English
Approval received for Paediatric Investigation Plan from EMA 5 pages 358.2KB
Regulatory Filings
2023-07-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.